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Alzheimer’s disease is one of the most common neurodegenerative disorders in elder population. The 
β-site amyloid cleavage enzyme 1 (BACE1) is the major constituent of amyloid plaques and plays a 
central role in this brain pathogenesis, thus it constitutes an auspicious pharmacological target for 
its treatment. In this paper, a QSAR model for identification of potential inhibitors of BACE1 protein 
is designed by using classification methods. For building this model, a database with 215 molecules 
collected from different sources has been assembled. This dataset contains diverse compounds with 
different scaffolds and physical-chemical properties, covering a wide chemical space in the drug-like 
range. The most distinctive aspect of the applied QSAR strategy is the combination of hybridization 
with backward elimination of models, which contributes to improve the quality of the final QSAR 
model. Another relevant step is the visual analysis of the molecular descriptors that allows guaranteeing 
the absence of information redundancy in the model. The QSAR model performances have been 
assessed by traditional metrics, and the final proposed model has low cardinality, and reaches a high 
percentage of chemical compounds correctly classified.
Alzheimer’s disease (AD) is a chronic and irreversible brain disorder, which mostly affect to age people. This neu-
rodegenerative disease is characterized by steady cognitive impairment, short-term memory loss, and problems 
with language. AD constitutes one of the main causes of death in the world, representing the majority of cases of 
dementia1. Actually, it is estimated that 47 million people live with dementia around the world, and according to 
projections it is expected that the number of cases grows to more than 131 million by 20502. Besides, dementia 
has an enormous economic impact. During 2016, the total estimated global cost of dementia was US$818 billion, 
and it will become a trillion-dollar disease by 2018.
Ample experimental studies about the hallmarks of AD conclude that deposition of amyloid plaques in the 
brains of Alzheimer’s patients constitutes one of the crucial causes of the disease progression3,4. The essential 
component of the amyloid plaques is the amyloid-β protein (Aβ)5, which is generated by subsequent cleavage of 
the amyloid precursor protein (APP) by two proteolytic enzymes β- and γ-secretase6,7. The whole biochemical 
mechanism of proteolytic cleavage depends on the protein-protein interactions between β-site amyloid cleavage 
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enzyme 1 (BACE1) and APP8. Due to several failures in clinical trials, there is currently some controversy with the 
use of BACE1 inhibitors. The possible reasons of the failure of BACE1 inhibitors are mainly three. One of them 
is that BACE1 inhibitors fail as they prevent amyloid production later in the course of illness and may be more 
effective if used earlier. The second one is about the complexity of AD, given the multifaceted nature of AD, it is 
unrealistic to expect that BACE1 inhibitors will be work alone9,10. And the last reason is the latter reason seems to 
be related to the side effects, since the conclusions of different studies show that to block completely the activity of 
BACE1 is not advisable due to severe side effects11. But even with these critical points, this way, the inhibition of 
BACE1, is a promising therapeutic strategy for instance BACE1 inhibitors with a multitarget profile12. It is evident 
that still more effort is needed today in this field.
During last years, several quantitative structure-activity relationships (QSAR) models have been developed 
in order to predict potential inhibitors for protein BACE113–17. QSAR methods correlate molecular structure to 
different biological properties such as activity or ADMET properties, providing a relevant data to help during 
the development of drug design projects18. A key step in QSAR studies is the definition or codification of the 
chemical structure by a diversity of molecular descriptors, such as constitutional, topological, thermodynamic, 
functional groups, quantum mechanical, geometrical, etc. Nowadays, the development of new cheminformatics 
software allows to calculate thousands of molecular descriptors19, but usually only a small subset of the calculated 
descriptors brings necessary information for generating the QSAR model of interest. Consequently, the accuracy 
of these models depends on the correct analysis and selection of computed descriptors as independent variables 
for the QSAR model definition. For all these reasons, the design of an effective QSAR model constitutes a chal-
lenging problem20.
Other kind of studies has employed the QSAR models to predict, using a new approach like Fragment 
Based-QSAR and Group Based-QSAR. This kind of studies consists of counting different chemical fragments and 
groups in the desired compounds or leads in order to optimize the QSAR models15,21,22. Goyal et al.23 used a group 
of 20 derivatives of the family of dihydropyridines (DHP) due to their good activities against BACE1 enzyme. 
Using Vlife MDS software24, 705 physicochemical descriptors were obtained and reduced to 311 independent 
variables. Several selection methods such a step-wise and searching algorithm among others were employed 
to correlate the biological information to descriptors information. Finally, statistical methods like partial least 
square (PLS), multiple regression and other techniques were used to obtain models with good correlation and 
predictive values.
On the other hand, several authors have performed QSAR approaches based on target properties that are 
correlated to the most important ligand-target interactions14 used PoseView25,26 and Ligand Explorer software27 
to find the most important ligand-target interactions of structures deposited in the PDB Bank28 visualizing and 
adjusting the best distance between the atom’s interactions. In this sense, two descriptors were obtained by the 
last procedure to predict the activity of BACE1 inhibitory compounds, the hydrophobic contacts at 4–5 Å and the 
number of hydrogen bonds between ligand and target.
Finally, Gupta et al.17 published a QSAR model integrated by four molecular descriptors that encoded 3D 
features of the compounds. These descriptors were chosen by combining a ranking approach, which computes 
the Pearson correlation between each descriptor and the biological activity, and a forward/backward selection 
approach. Using these descriptors, different QSAR models are inferred by using multiple linear regressions. As a 
final point, it is interesting to mention that Gupta employs a methodology for computing the molecular descrip-
tors equivalent to the applied in our study, for this reason, we have decided to compare our QSAR models with 
those obtained by Gupta´s group.
In this paper, we present novel QSAR models for predicting putative inhibitors for protein BACE1. Our pro-
posal combines the application of several machine learning methods, model hybridizing strategies, backward 
elimination and visual analytics, in order to choose the most informative subset of molecular descriptors for 
building the QSAR models. Another distinctive aspect of our approach is the characterization of the QSAR 
modelling problem as a classification system, which helps to achieve a straightforward interpretation of the pre-
dictions. The QSAR classification models obtained from our experiments have been analysed, hybridized and 
compared, from a chemical and mathematical perspective, with Gupta’s models to compare the strengths and 
weaknesses of proposed models as virtual screening methods.
Results
Database. A database with 215 molecules was assembled, where the half maximal inhibitory concentration 
(IC50) values of the compounds were extracted from the literature and web servers (the complete database is 
shown in the Table S1 of the Supporting Information). All the compounds used on the dataset were obtained from 
different sources like pharmaceutical industries or web servers like PDB Bank and CheMBL29 among others. In 
order to obtain robust models with a wide applicability domain, the dataset is formed by compounds chemically 
diverse, with different scaffolds, reflecting a wide chemical space. All of them have been tested experimentally on 
the BACE1 enzyme with a reported IC50 value.
Is important have a representative chemical space in QSAR studies, consequently, is necessary to build a struc-
tural diverse set of compounds in order to achieve it. Following this aim, the dataset was analysed characterizing 
its drug-like properties from a physicochemical point of view. Thus, two different approaches have been used to 
analyze our datasets diversity, from the point of view of structural and drug-like.
For the drug-like analysis of the compounds, we used a Qikprop’s module: Small-Molecule Drug Discovery 
Suite in Schrödinger30, which through a set of mathematical functions and structural analysis allows to predict 
physical-chemical properties such as polar surface area, logP and others. Among the set of properties that the 
module is able to analyze; for Fig. 1, the molecular weight (MW) was chosen and compared to the coefficient 
QPlogBB and colored by the percentage of human oral absorption (%); these last two are physical-chemical prop-
erties predicted by the program.
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Molecular weight property, included as one of the 4 Lipinski’s rules31 is one of the parameters analyzed for 
the dataset. In general, compounds with a molecular weight greater than 500 will not be good candidates as 
drugs-like compounds, this is considered as a determinant factor. However, in this case, the special topology of 
the BACE1 enzyme, which presents a large cavity around 10–15 Å, makes important for the inhibition to stablish 
several protein-ligand interactions in different key points of the pocket far from one another. For this reason, 
BACE1 drug discovery programs are based in bigger molecules in order to obtain low nanomolar inhibitors 
comparing with other targets.
The QPlogBB coefficient represents a prediction of the ability of the different compounds to cross the 
blood-brain barrier for the analysed compounds. Due to the location of the BACE1 enzyme, this property has to 
be taken into account when selecting compounds that are desired to present some type of inhibitory enzymatic 
effect in vivo. The calculated values of that parameter are in the following interval [−3.0/1.2], the compounds in 
the dataset present a wide distribution for this value in Fig. 1A. The more positive the value is, the more ability 
of the compound for crossing the blood-brain barrier. On the contrary, compounds that present negative values 
theoretically will not be able to cross it satisfactorily. As a result, it is observed that the majority of the compounds 
in the database is in the upper side of the figure. We can confirm the study with dopamine that present negative 
values because it is too polar and is not able to cross that barrier well.
Also the (%) Human oral absorption was analyzed due to the fact that drug-like compounds must be absorbed in 
an adequate rate by the human body as one of the key ADME (Absorption, Distribution, Metabolism and Excretion) 
properties. This value is obtained through a multiple linear regression of a series of parameters such as the number 
of rotatable bonds, and the permeability or solubility of the compounds at the time of predicting that property. In 
the Fig. 1A, we observe that the vast majority of the compounds present values of human oral absorption over 50%.
To conclude the characterization, Fig. 1B illustrates the drug-like behaviour of the dataset. The lower number of 
starts and violation number of Lipisnki rule, the better drug-like profile. Furthermore, most of these violations are 
in relation with MW, something expected due to the bigger size of molecules in medicinal chemistry programs for 
BACE1 inhibitors as stated before. Therefore, as no compounds present more than 2 violations of Lipinski rule of 5, 
it is possible to confirm that their properties make them likely orally active drugs in humans. A detailed supplemen-
tary statistical analysis of several properties is included in the Supporting Information (Table S2 and Figs S1–S6).
Figure 1. Graphical representation of physicochemical and drug-like properties of the BACE1 dataset. (A) 
Dispersion of compounds regarding logP prediction (x-axis) and logBB prediction (y-axis). Colors are defined 
by % human oral absorption. (B) Dispersion of the dataset according to molecular weight (x-axis) and a 
parameter related to physical-chemical properties of commercially available drugs (y-axis). The color is defined 
by the number of violations of the rule of 5.
4Scientific RepoRts |          (2019) 9:9102  | https://doi.org/10.1038/s41598-019-45522-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Data pre-processing. As it was mentioned before, the dataset is integrated by 215 molecules. The target var-
iable for this study is BACE1 inhibitory activity (half maximal inhibitory concentration (IC50) of each compound. 
The values are typically expressed as molar concentration. For classification purpose, it was defined one threshold 
(1000 nM) for discretization of the IC50 values in order to define two classes of compounds: High Activity (HA) 
as inhibitors (IC50 ≤ 1000 nM), and Low/Null Activity (LA/NA) as inhibitors (IC50 > 1000 nM). Applying this 
criterion, the 215 molecules of this dataset are distributed in 126 HA compounds and 89 LA compounds.
Molecular descriptor calculation. DRAGON tool was the software used to compute the Molecular 
descriptors (MDs)32. In Table 1, a summary of the quantity of MDs calculated, clustered by family and type (0D, 
1D, 2D, 3D and others), is detailed. A total number of 1867 MDs were finally incorporated to the BACE1 database 
after removing redundant descriptors with correlation coefficients bigger than 0.95.
In silico experimental design. The employed protocol to develop QSAR models by feature selection is dis-
played in Fig. 2. In the first phase the IC50 values are discretized using target discretization thresholds explained 
before. Next, these molecules were optimized to the configuration of minimum energy and, after that, 1867 
molecular descriptors were computed using DRAGON software. After that, 25% of the molecules has been left 
apart for the last step of external validation, and the 75% of the remaining compounds were used for the feature 
selection and model construction steps. In the second phase, to select the subsets of molecular descriptors (MDs), 
we used three different approaches from the set of variables returned by DRAGON. The first approach uses 
DELPHOS tool, which run a machine learning method for selection of MDs in QSAR modelling33. DELPHOS 
infers multiple alternative selections of MDs for defining a QSAR model by applying a wrapper method34. In this 
case, twenty putative subsets had been computed. From them, we chosen two subsets, Subsets A and B (Table 2), 
since these subsets show the lowest relative absolute error (RAE) values reported by DELPHOS and small num-
bers of MDs.
The second one was generated by WEKA tool35, applying as feature selection method the Wrapper Subset 
Evaluator with Random Forest as classifier and Best First technique as Search Method. The selected subset is inte-
grated by ten MDs and it was named Subset C. The most elevated cardinality of this subset is manageable but not 
desirable, because the physicochemical interpretation of resulting QSAR models usually became a cumbersome 
and time-consuming process. Besides, the QSAR models integrated by many variables usually suffer of poor 
generalization in statistical terms. The last one was provided by the scientific literature. In particular, the Subset D 
corresponds to the selection of four MDs recommended in Gupta et al.17.
Later, the performance of these four subsets has been evaluated by inferring QSAR classification models. 
All classifiers have been generated by WEKA software using alternative machine learning methods: the Neural 
Networks (NN), the Random Forest (RF), and the Random Committee (RC). Recent studies have shown that 
does not exist a more advisable strategy for learning the QSAR models from the subsets of descriptors36. Random 
Forest and Random Committee are ensemble methods that combine different models with the aim to obtain 
accurate, robust and stable predictions. The first one implements an ensemble of decision trees where each tree is 
trained with a random sample of the data and the growth of these trees is carried out with a random selection of 
features. In a similar way, Random Committee allows building an ensemble of a base classifier that is chosen, for 
example, a neural network or a decision tree. On the other hand, Neural Networks are configurations of artificial 
neurons interconnected and organized in different layers to transmit information. The input data crosses the 
neural network through various operations and then the output values are computed. In this sense, we decided 
to test these several methods to infer the classifiers. The parameter settings provided by default for WEKA, were 
used in the experiments for each inference method. Several metrics were calculated using WEKA, regarding 
the performance assessment: the percentage of cases correctly classified (%CC), the average receiver operating 
characteristic (ROC) area, and the confusion matrix (CM). In all cases, the stratified sampling and 10-fold cross 
validation methods provided per default by WEKA were applied. The best QSAR models obtained per each subset 
is reported in Table 3, where the classifier with best performance is highlighted.
In the third phase, the first step corresponds to a QSAR model hybridization experiments. These strategies 
that combine MD subsets obtained from different methodologies has been useful tested in other scenarios37–41 
Type of Molecular Descriptors # MD Type of Molecular Descriptors # MD
constitutional descriptors 48 geometrical descriptors 74
topological descriptors 119 RDF descriptors 150
walk and path counts 47 3D-MoRSE descriptors 160
connectivity indices 33 WHIM descriptors 99
information indices 47 GETAWAY descriptors 197
2D autocorrelations 96 functional group counts 154
edge adjacency indices 107 atom-centred fragments 120
burden eigenvalues 64 charge descriptors 14
topological charge indices 21 molecular properties 29
eigenvalue-based indices 44 2D binary fingerprints 780
Randic molecular profiles 41 2D frequency fingerprints 780
Table 1. Number of molecular descriptors of each family computed for the database compounds.
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and for this reason it was also evaluated in this work. The main goal of these experiments is to improve the accu-
racy obtained for the best model by adding features included in remaining subsets. Following this idea, three 
hybridized subsets were defined by combining the subset D, which achieves the best performance in Table 3, with 
each other subsets in a pairwise fashion. Besides, a fourth hybrid subset was defined as the union of all subsets. 
These straightforward hybridizations are reported in Table 4.
Once the hybridized subsets were defined, the next step was the evaluation of them by inferring QSAR classi-
fication models employing identical experimental conditions and criteria applied to the original non-hybridized 
subsets (Table 5). Subset HS1 was the best hybridized subset considering such as accuracy as low cardinality.
From this table, it is possible to observe that the QSAR model inferred from the pairwise hybridization 
between subsets A and D overcame the performance obtained by the models generated from these subsets by 
alone. However, at this point, it is valid to ask whether there is any subset of the hybridized subset HS1, different 
from subsets A and D (HS1) that can achieve models with even better performance. This is possible because some 
of the molecular descriptors provided by subsets A and D can be redundant or introduce some noise to the clas-
sification procedure affecting the generalization properties of the QSAR models.
Figure 2. Graphical scheme of experiments reported for the prediction of inhibitors of protein BACE1 by 
applying QSAR modelling.
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To evaluate the relevance of each molecular descriptor a combinatorial reduction analysis, commonly known 
as backward elimination was performed. This analysis consists of eliminating a molecular descriptor of HS1 
each time and calculating its performance. This process is repeated until not improvement of the performance is 
observed (see Tables S3–S5 of the Supporting Information). The higher performance was obtained by removing 
two MD with a cardinality subset of 6. The results of the best QSAR classifiers obtained in each step are included 
in Table 6, where the minus operator denotes the deletion of one MD from the subset. In the first step, eight 
subsets with cardinality seven were obtained by removing one molecular descriptor from HS1 at once, and their 
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Table 2. Molecular descriptors of DRAGON associated with the selected subsets.
Subset Method %CC ROC Confusion Matrix
















Table 3. Performances of the best QSAR classifiers obtained per each subset during external validation. The 
best model is highlighted in bold.
Hybridized Subset Combined Subsets Cardinality
HS1 Subset D ∪ Subset A 8
HS2 Subset D ∪ Subset B 8
HS3 Subset D ∪ Subset C 14
HS4 Union of all subsets 21
Table 4. Hybridized subset obtained from the union of different subsets.
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performances were tested following the same experimental conditions described before. The higher performance 
is obtained by removing the molecular descriptor MW (%CC = 85%), improving the HS1 accuracy (first row of 
the Table 6).
In the second reduction step, seven subsets of cardinality six were obtained by alternative removing one 
MD at once from the reduced subset HS1-MW. The performance of the best QSAR model inferred from each 
reduced subset is reported in the second row of the Table 6, where the model with higher performance is 
obtained using HS1-MW-RDF080m. This model preserves the %CC de subset HS1-MW but using one MD less 
and increases the value of the ROC curve to 0.88. In the third backward elimination step, six subsets of cardinal-
ity five were obtained by alternative removing one MD at once from the subset HS1-MW-RDF080m. The per-
formances of the best QSAR model inferred from each of these new reduced subsets are reported in the third 
row of the Table 6. In this case, the model with higher accuracy corresponds to HS1-MW-RDF080m-N-069, 
but the performance falls to 83%. For this reason, the final best model (HS1-MW-RDF080m) includes the final 
selection of MDs is integrated by the following subset of MDs: GGI7, H1e, H6m, Mor31p, N-069 and nCrs. As 
summary, Fig. 3 shows a performance comparison of best QSAR models obtained in each step of our experi-
mental work. The percentage of corrected classified molecules is expressed as a ratio in order to improve the 
plot visualization.
It is important to note that this final subset does not fully include the subset A neither the subset D, because 
one descriptor of both subsets was removed during the reduction of the hybrid subset HS1. One logical question 
that can be formulated at this point it is why the traditional feature selection approaches (DELPHOS, WEKA and 
Gupta’s methodology) do not find directly this subset of cardinality six. This occurs because feature selection con-
stitutes a NP-hard problem in computational complexity theory and, therefore, any algorithm used for addressing 
this problem will explore some part of the huge combinatorial space associated to all possible subsets of MDs. For 
this reason, the hybridization of subsets obtained by different FS strategies together with the backward elimina-
tion can be useful for improving the solutions provided by traditional FS methods.
Concerning to their physicochemical meanings, H1e and H6m are GETAWAY (Geometric Topology and 
Atom Weights Assembly) descriptors. H1e is an H index autocorrelation of lag 1 weighted by Sanderson elec-
tronegativity and H6m is an H index autocorrelation of lag 6 weighted by atomic mass. This type of descriptors is 
related to the influence of atoms in the determination of the molecular form. On the other hand, GGI7 belong to 
2D autocorrelations descriptors class and is the topological charge index of order 7. Another descriptor is nCrs 
that represents the number of ring secondary C (sp3) and belongs to the Functional group counts. The descrip-
tor N-069 belongs to the Atom-centered fragments class and indicates the number of substructures in which a 
Subset Cardinality Method %CC ROC Confusion Matrix
















Table 5. Performances of the best QSAR classifiers obtained per each hybridized subset during external 
validation. The best model is highlighted in bold.
Subset Step Cardinality Method %CC ROC Confusion Matrix












Table 6. Performances during external validation of the best QSAR classifiers inferred for HS1 reduced subsets 
in each step. The final model has 6 molecular descriptors, an 85% of cases correctly classified and a ROC curve 
of 0.88.
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sp3 nitrogen atom is connected by a simple bond to an electronegative atom or an aromatic substituent. Lastly, 
Mor31p is a 3D-MoRSe (Molecule Representation of Structures Based on Electron diffraction) descriptor that 
represents the signal 31 weighted by polarizability. This class of descriptors captures the three-dimensional struc-
ture of a molecule and expresses distinctive characteristics of it.
Finally, as last phase of the proposed methodology, it was analyzed the pairs correlation between these six 
descriptors by using VIDEAN39. This tool uses visual analytical methods for molecular descriptors analysis in 
statistical terms. Figure 4 shows the relationship between the descriptors in the Kendall correlation mode. In this 
representation, the light orange and light blue tones of the edges (correlation) between the nodes (descriptors) are 
showing a low level of correlation. This result is the expected one, confirming that each descriptor is contributing 
unique information to the model.
Random experiments for assessing the risk of correlation by chance. In this section, we present 
two random experiments in order to assess the risk of chance correlation both in the final subset of MDs selected 
by our methodology and in the final QSAR model inferred from these MDs. Whenever in a QSAR modelling 
method a “best” combination of a few (m) descriptors is selected from a pool of many (M) descriptors in order to 
best fit given target variable, there is an enhanced risk of chance correlation42,43. The risk is boosted (compared to 
using a predefined subset of descriptors) due to the number of possible models considered, which for increasing 
m and M speedily exponentially grows to huge orders of magnitude:
= −MMCm M!/(m!( m)!)
Figure 3. Performance during external validation of the best QSAR model achieved in each experimental step.
Figure 4. Kendall correlation among descriptors of the best model.
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Among so many potential subsets of m descriptors, a few of these combinations are likely to fit the data rea-
sonably well by chance, i.e., without having a true association with the response variable. Therefore, descriptor 
selection methods, led by a typical measure of fit, are blind with respect to presence or absence of such a true asso-
ciation. Nowadays this problem, also now as selection bias6, has become urgent because the number of molecular 
descriptors available in computer programs has been significantly increasing during last decades44.
In order to address this problem, the first step consists into evaluating if the final subset of MDs selected by 
our methodology has an accuracy performance significantly higher than the achieved by MD subsets selected 
randomly. Once this risk can be left behind, the second step should be to determine if our proposed QSAR model, 
inferred from the final subset of MDs by using machine learning, truly learned how to segregate compounds 
among the different classes associated to the target variable. In other words, we want to assess if our QSAR model 
does not classify the compounds randomly.
For the first step, a feature selection randomization experiment (fs-randomization) has been executed. In 
this experiment, a thousand combinations of six MDs, the same cardinality of the final subset, selected by our 
methodology, has been randomly selected from the original pool of features integrated by 1867 MDs (see Fig. 5). 
Therefore, from each random subset, a QSAR model is inferred following the same experimental conditions and 
criteria used for learning our final QSAR model. Finally, the accuracies (as a percentage of corrected classified 
samples) of the QSAR models obtained from these random subsets had been computed. The average accuracy 
(%CC) obtained by the fs-randomization was 69%, and only three of the thousand random trials achieved a 
performance similar to our final subset (around 85%). Therefore, the performance of the MD subset selected by 
our methodology is located in the percentile 99 of the accuracies distribution obtained by the fs-randomization, 
showing a performance significantly higher than the random subsets.
For this second step, a y-randomization experiment has been executed. This method consists of randomly 
shuffled the values of the target variable (y-variable) both in the training set and external validation set, leaving 
the MDs values intact. Then, a new QSAR model is applied to these scrambled data following the same exper-
imental conditions used to infer the original QSAR model. Every run will yield estimates of the accuracy of 
the QSAR model, which are recorded. If in each case the scrambled data give much lower accuracy values than 
the original data, then we can be confident about the relevance of the “real” QSAR model. This methodology is 
“probably the most powerful validation procedure” for assessing the risk of obtaining QSAR models by chance 
correlation45, and combined with the fs-randomization allows us to achieve confident QSAR models44. The 
average accuracy (%CC) obtained by the y-randomization was 53% (see Fig. 6), and none of the thousand ran-
dom trials achieved a performance similar to our final subset (best random performance was 75%). Therefore, 
from these results, we can confidently discard the risk of chance correlation in the final QSAR model proposed 
in this work.
Figure 5. Results of the feature selection randomization experiment.
Figure 6. Results of the y-randomization experiment.
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Materials and Methods
Preparation of databases. Ligand preparation. The BACE1 dataset on SMILES format were converted 
to 3D structures using LigPrep46 software implemented on Maestro Suite47. LigPrep is a 2D-to-3D conversion 
application that carries out the addition of hydrogen atoms and includes the generation of possible tautomers, 
stereoisomers and ring conformations using molecular mechanics force fields. The tool also calculates the ioniza-
tion state of the molecule at a selected pH range. In order to perform our studies, possible states were generated 
at pH 7.3 with the aim of obtaining the most suitable ionization states of the molecules at physiological pH. The 
ionization states were assigned with Epik module48. Also, no tautomers were generated and all the compounds 
were desalted. In this process, the search has been restricted to obtain only one low energy ring conformation, 
as well as one stereoisomer among all that can be found by the tool. The final step of the preparation is an energy 
minimization of the 3D conformers generated using the OPLS2005 force field49.
Different ionization states and conformers of the same molecules were reduced to keep the most suitable 3D 
structure per initial compound. This preparation is a critical step to carry out further studies with these com-
pounds, such as the physicochemical properties calculation to characterize the dataset.
Drug-like properties calculation. All the prepared molecules were studied using Qikprop application of the 
Small-Molecule Drug Discovery Suite in Schrödinger, an accurate software that predicts structurally signifi-
cant 2D and 3D properties and pharmaceutically relevant characteristics of chemical compounds. Absorption, 
Distribution, Metabolism, and Excretion (ADME) properties were predicted using this tool where a total of 44 
properties are calculated. The program also calculates properties like molecular weight, polar surface area, molec-
ular volume, QPlogPo/w (predicted octanol/water partition coefficient), number of H-bond donors and acceptor 
groups, and violations related to the Lipinski’s Rule of 5 and Jorgensen’s Rule of 3 and allows to filter out com-
pounds with clear-cut undesirable properties for drug discovery.
Statistical analysis of the database. All the data obtained in the previous step was further analyzed, using SPSS 
software50. Statistical parameters were calculated for the database of compounds, such as modal value, average, 
median, standard deviation or variance for some key physicochemical parameters of the analysis. Furthermore, 
several histograms are shown in the Supporting Information where the frequency of the different values can be 
found grouped by properties.
Software used for processing molecular descriptors. DRAGON32 is a calculation of molecular 
descriptors tool. It provides almost 5,000 molecular descriptors of different types: 0D, 1D, 2D, and 3D. These 
molecular descriptors can be used to evaluate molecular structure-activity/property relationships of molecule 
databases. DRAGON required to calculate their molecular structure files, and also can deal with H-depleted 
molecules and 2D-structures.
Machine learning tools used for feature selection and classification models. DELPHOS is 
a descriptors selection tool that implements a wrapper multi-objective optimization technique based on two 
phases. In the first phase, a wrapper method and different machine learning algorithms are used to perform an 
exploration within the search space and find appropriate subsets of descriptors. Then in the second phase, a final 
subset selection is performed using the selections of the first phase and metrics for a more accurate prediction. In 
this way, DELPHOS allows identifying relevant subsets of descriptors related to the property under study33,34,51.
VIDEAN is a visual analytics tool that combines statistical methods with interactive visualizations for helping 
in the selection of a subset of molecular descriptors for predicting a target property. It shows the relationships 
and interactions between the molecular descriptors and the target property in different information panels. A 
basic visualization used in this work consists in an undirected graph, where nodes represent each descriptor, the 
size of the node indicates the correlation between this node and the target property, and colored edges reflect the 
pairwise correlation between the descriptors that it connects. More detailed information about this software is 
available in Martinez et al. 201539.
Weka tool is a machine learning algorithms suit, for data mining tasks35. The learning methods used in this 
work are:
Wrapper Subset Evaluator: method to evaluate a set of attributes using a learning technique. It uses cross val-
idation to estimate the precision52.
Best first: is a method that performs searches in the space of subsets of attributes through a greedy hill climb-
ing and using a backtracking strategy.
Neural Networks: a multilayer perceptron method that use back-propagation to classify instances. The 
network, is allowed to be monitored and modified during training time. The nodes are all sigmoid, except for 
numeric class.
Random Forest: allows constructing a Random Trees forest53. The random trees considers K randomly chosen 
attributes at each node for build a tree. Performs no pruning, and allow class probabilities estimation (or target 
mean in the regression case) based on a hold-out set (back fitting).
Random Committee: this method allows to build an ensemble of randomized base classifiers. Each base clas-
sifier is built based on the same data, but using a different random number seed. The final prediction is a straight 
average of all predictions generated by each individual base classifiers.
Methods used for random experiments. These methods aim to evaluate the risk of random correlation 
in both the subset of molecular descriptors selected through a specific methodology and in the final QSAR model 
obtained from these descriptors.
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fs-randomization (feature selection randomization): is a method that consists of randomly selecting a number 
n of molecular descriptors from the original features set, where n is the cardinality of the MDs subset that have 
been selected by a specific technique. Then, from these random MDs and with the original values of the target 
property, a new model is inferred following the same experimental criteria that were used to obtain the final 
QSAR model. Finally, the accuracy value (percentage of correctly classified samples) is reported. This method is 
applied repeatedly in order to obtain a distribution of values with statistical significance.
y-randomization: is a technique that randomly reorders the values of the target property (y-variable) both in the 
training set and the external validation set, without modifying the values of the MDs. To apply this technique, the n 
MDs of the final QSAR model are used. In this way, a new model is generated following the same experimental con-
ditions that were used to obtain the final QSAR model, and the accuracy value is reported. Like fs-randomization, 
this process is repeated a fixed number of times in order to obtain a distribution of values with statistical significance.
Additional information on these and other techniques for randomizing experiments in QSAR modeling can 
be found in44.
Conclusions
Alzheimer’s disease is one of the neurodegenerative disorders with stronger impact in elder population around 
the world. A promising target for its pharmacological treatment is the β-site amyloid cleavage enzyme 1 (BACE1). 
Several studies proposed that BACE1 inhibitors have high therapeutic potential for decelerating the long-term 
progression of AD, and during last decade several quantitative structure-activity relationships (QSAR) models 
have been proposed in the literature.
In this paper, a new QSAR model for virtual screening of potential inhibitors of BACE1 protein has been 
developed using a novel computational strategy. The main goal of the proposed strategy is to obtain accurate 
QSAR models integrated by a minimum number of molecular descriptors, because models with large number 
of descriptors suffer of poor generalizability and complex interpretability. QSAR approaches based on machine 
learning use feature selection methods for choosing the most informative subset of molecular descriptors, but 
all these algorithms only explore a fraction of the whole combinatorial space of potential subsets. Therefore, 
these methodologies cannot guarantee a QSAR model of minimum size. For this reason, our proposal combines 
different methodologies of feature selection, model hybridization approaches, backward elimination and visual 
analytics to improve the performance of the traditional QSAR methods.
Thanks to this methodology we have developed a robust QSAR model, improving around an 8% regarding 
the Gupta’s model in terms of both central performance metrics (percentage of corrected classified molecules and 
average ROC values) by preserving a low cardinality model. Additionally, the risk of chance correlation in the 
proposed QSAR model has been discarded by executing and analyzing both feature selection randomization and 
y-randomization experiments. Furthermore, the wide chemical diversity of the database used in our study compared 
to previous studies enhances the applicability of our model. Therefore, the results obtained by this novel strategy 
show that our approach contributed to achieve a QSAR model that can be a useful virtual screening method for 
prediction of BACE1 inhibitors. Nevertheless, as any QSAR model generated by machine learning, it is important 
to know that these classifiers preserve their levels of accuracy for molecules structurally similar to the chemical 
compounds used during the training of the model. For this reason, potential users of these models should be employ 
applicability domain methods. As a future work, we plan to evaluate this new methodology in the development of 
other classification models and continue testing our QSAR model for predicting BACE1 over other datasets.
Description of additional data files. The following additional data are available with the online version 
of this paper. “Supplementary Information” contains more information about the dataset, its statistical properties 
and additional results about intermediate calculations during the backward elimination analysis.
Data Availability
All data generated or analyzed are available upon request.
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